NOVEL DIFFERENTIATION ANTIGENS OF NORMAL AND NEOPLASTIC HEMATOPOIETIC AND LYMPHOID CELLS (ACCORDING TO HLDA9 AND HLDA10 INTERNATIONAL WORKSHOPS)

Philchenkov A.A., Gluzman D.F., Ivanivska T.S.

• R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine

The development of the methods for monoclonal antibody (MAb) production revolutionized the immunology as well as other fields of biology and medicine. The hybridome technology contributed to the large-scale production of highly sensitive reagents capable to react with the antigens of surface membrane of leukocytes and cells of other tissues and organs in a highly speci­fic manner. However, the MAbs of the same specificity obtained in different laboratories were labeled under different names. This problem was largely resolved when the classification (nomenclature) of the human leukocyte antigens identified with the aid of the MAbs of the same specificity was adopted by the International Union of Immunological Societies and approved by World Health Organization. The review systematizes the current information about novel clusters of differentiation (CD) comprising 27 human leukocyte differentiation antigens (HLDA) accepted on the 9-th and 10-th HLDA International Workshops (2010 and 2014). The data on the genes coding for CD molecules, their families, chromosome location and mRNA expression in organs and tissues have been presented. The information on molecular weight of CD molecules, their tissue specificity and subcellular localization, the functions of these molecules and the key mechanisms involved in their realizations has been reported. The special emphasis is focused on the possible clinical applications of the novel CD in oncohematology for diagnosis and prognostication of the diseases as well as the targets for therapy. The data summarized in the article improve the up-to-date knowledge on the mechanisms of the initiation and progression of the tumors of hematopoietic and lymphoid tissues allowing for the advancement in differential diagnosis, monitoring and treatment of hematological malignancies.